| Dr Peter Farrugia, MD | |
|
340 Route 34 Ste 201, Colts Neck, NJ 07722-2434 | |
| (732) 487-3636 | |
| (732) 487-3635 |
| Full Name | Dr Peter Farrugia |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 20 Years |
| Location | 340 Route 34 Ste 201, Colts Neck, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003142530 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 25MA08938500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Monmouth Medical Center | Long branch, NJ | Hospital |
| Centrastate Medical Center | Freehold, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Heart And Vascular Of Central Jersey | 4486074549 | 3 |
News Archive
NanoPacific Holdings, Inc. (NPH) announces the acquisition of an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. Under the terms of the agreement between NPH and UCLA, NPH will have an exclusive worldwide license of a system composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles.
Smoking bans are not only shrinking tobacco firm's market at home but limiting their ability to invest in markets abroad, according to new research.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Data show that concurrent with the opioid overdose crisis, there has been an increase in hospitalizations of people with opioid use disorder (OUD).
› Verified 1 days ago
| Entity Name | Monmouth Medical Center Faculty Practice Plan, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023064441 PECOS PAC ID: 8527971563 Enrollment ID: O20031106000595 |
News Archive
NanoPacific Holdings, Inc. (NPH) announces the acquisition of an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. Under the terms of the agreement between NPH and UCLA, NPH will have an exclusive worldwide license of a system composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles.
Smoking bans are not only shrinking tobacco firm's market at home but limiting their ability to invest in markets abroad, according to new research.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Data show that concurrent with the opioid overdose crisis, there has been an increase in hospitalizations of people with opioid use disorder (OUD).
› Verified 1 days ago
| Entity Name | Barnabas Health Medical Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206420 PECOS PAC ID: 0648172809 Enrollment ID: O20040127000361 |
News Archive
NanoPacific Holdings, Inc. (NPH) announces the acquisition of an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. Under the terms of the agreement between NPH and UCLA, NPH will have an exclusive worldwide license of a system composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles.
Smoking bans are not only shrinking tobacco firm's market at home but limiting their ability to invest in markets abroad, according to new research.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Data show that concurrent with the opioid overdose crisis, there has been an increase in hospitalizations of people with opioid use disorder (OUD).
› Verified 1 days ago
| Entity Name | Mmc Provider Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932647872 PECOS PAC ID: 9133555626 Enrollment ID: O20200131000598 |
News Archive
NanoPacific Holdings, Inc. (NPH) announces the acquisition of an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. Under the terms of the agreement between NPH and UCLA, NPH will have an exclusive worldwide license of a system composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles.
Smoking bans are not only shrinking tobacco firm's market at home but limiting their ability to invest in markets abroad, according to new research.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Data show that concurrent with the opioid overdose crisis, there has been an increase in hospitalizations of people with opioid use disorder (OUD).
› Verified 1 days ago
| Entity Name | Advanced Heart And Vascular Of Central Jersey |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588277503 PECOS PAC ID: 4486074549 Enrollment ID: O20201012002481 |
News Archive
NanoPacific Holdings, Inc. (NPH) announces the acquisition of an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. Under the terms of the agreement between NPH and UCLA, NPH will have an exclusive worldwide license of a system composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles.
Smoking bans are not only shrinking tobacco firm's market at home but limiting their ability to invest in markets abroad, according to new research.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Data show that concurrent with the opioid overdose crisis, there has been an increase in hospitalizations of people with opioid use disorder (OUD).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Peter Farrugia, MD 340 Route 34 Ste 201, Colts Neck, NJ 07722-2434 Ph: (732) 487-3636 | Dr Peter Farrugia, MD 340 Route 34 Ste 201, Colts Neck, NJ 07722-2434 Ph: (732) 487-3636 |
News Archive
NanoPacific Holdings, Inc. (NPH) announces the acquisition of an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. Under the terms of the agreement between NPH and UCLA, NPH will have an exclusive worldwide license of a system composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles.
Smoking bans are not only shrinking tobacco firm's market at home but limiting their ability to invest in markets abroad, according to new research.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.
Data show that concurrent with the opioid overdose crisis, there has been an increase in hospitalizations of people with opioid use disorder (OUD).
› Verified 1 days ago
Nancy Castellucci Peters, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 281 Route 34, Suite 813, Colts Neck, NJ 07722 Phone: 732-431-2620 Fax: 732-431-3707 | |
Lisa Gualberti-girgis, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 9 Professional Cir, Suite 101, Colts Neck, NJ 07722 Phone: 732-431-1520 Fax: 732-431-1567 | |
Dr. Michael L Bernstein, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 65 Highway #34, Suite 200, Colts Neck, NJ 07722 Phone: 732-431-2620 Fax: 732-780-0014 | |
Anthony G. Chen, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 281 State Route 34 Ste 813, Colts Neck, NJ 07722 Phone: 732-431-2620 Fax: 732-431-2620 | |
Dr. Aileen C Estavillo, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 281 Route 34 Ste 813, Colts Neck, NJ 07722 Phone: 732-431-4620 Fax: 732-431-3707 | |
Joann Gualberti, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 9 Professional Cir, Suite 101, Colts Neck, NJ 07722 Phone: 732-431-1520 Fax: 732-431-1567 |